Section
A pilot study shows that combining GLP-1 analogues and SGLT2 inhibitors with lifestyle changes significantly reduces body weight and albuminuria in overweight Type 1 diabetes patients with CKD, though glycemic and blood pressure improvement
A randomized clinical study demonstrates that while SGLT2 inhibitors alone may induce urinary dysbiosis and increase pathogen risk, combining them with DPP-4 inhibitors restores a healthy urinary microbiota, potentially improving patient co
A new precision medicine model identifies high-benefit patients for SGLT2 inhibitor treatment even when albumin levels appear normal, potentially preventing 10% more kidney failure events than current guidelines that rely solely on albuminu
A cross-sectional analysis of the HOPE Consortium Trial reveals that chronic pain in hemodialysis patients is widespread, frequently musculoskeletal and neuropathic, and strongly associated with psychological and sociodemographic factors ra
Recent data highlights that GLP-1 receptor agonists (GLP1-RAs) reduce cardiovascular risk in patients with chronic kidney disease (CKD), yet real-world prescription rates remain alarmingly low despite these proven benefits across various st
A 12-week randomized trial demonstrates that dapagliflozin significantly reduces arterial stiffness and modulates fluid dynamics in patients at cardiovascular risk, regardless of diabetes status, providing a mechanistic basis for its broad
The SOUL trial demonstrates that oral semaglutide significantly slows the annual decline of estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes and cardiovascular disease, despite not meeting the primary composite k
A nationwide Danish study suggests SGLT2 inhibitors offer superior protection against chronic kidney disease and acute kidney injury compared to GLP-1 receptor agonists in patients with type 2 diabetes, particularly for primary prevention.
A sub-analysis of the FIRE trial demonstrates that physiology-guided complete revascularization significantly reduces major adverse cardiovascular events in patients aged 75 and older, irrespective of baseline kidney function, without incre
A prespecified analysis of the FINEARTS-HF trial demonstrates that the mineralocorticoid receptor antagonist finerenone consistently reduces cardiovascular death and heart failure events in patients with HFmrEF/HFpEF, regardless of baseline
Recent clinical evidence identifies Interleukin-6 (IL-6) as a critical driver of cardiovascular events. The ZEUS trial and recent LoDoCo2 analyses suggest that targeting IL-6 with ziltivekimab may significantly reduce risk for patients with
A large-scale study using UK Biobank data reveals that adhering to a Planetary Health Diet significantly lowers the risk of chronic kidney disease, emphasizing the dual benefits of plant-forward, sustainable eating for both personal health
A large-scale multi-cohort study involving nearly 190,000 participants reveals that the EAT-Lancet reference diet, measured by the Planetary Health Diet Index, reduces the risk of incident chronic kidney disease, particularly among women, a
Recent research from the UK Biobank reveals that a sustainable, plant-forward diet can lower chronic kidney disease risk by 26%, offering a dual solution for environmental and personal health.
The FIVE-STAR trial demonstrates that while finerenone significantly reduces albuminuria in patients with T2D and CKD, it does not improve arterial stiffness (CAVI). These findings suggest that its cardiorenal benefits are primarily driven
The FIVE-STAR trial reveals that finerenone’s cardiorenal benefits stem from reducing internal kidney pressure rather than improving arterial stiffness, offering a new perspective on managing type 2 diabetes and chronic kidney disease
The Navigate-Kidney trial demonstrates that community health worker support significantly improves interdialytic weight gain, dialysis adherence, and patient activation among Hispanic and Latino individuals on hemodialysis, addressing criti
This article explores a novel 3-year prognostic score for Fabry Disease cardiomyopathy, integrating CMR-derived T1 values, LV mass, and LGE extent to predict adverse events, emphasizing the negative predictive value of normal T1 mapping.
A large-scale multicenter study reveals that hospitals with higher utilization rates of continuous kidney replacement therapy (CKRT) achieve significantly lower 90-day mortality for critically ill AKI patients compared to low-utilization ce
A large-scale multicenter study reveals that 46.6% of severe AKI survivors in India and Southeast Asia experience major adverse kidney events (MAKE) within two years, with mortality and new-onset chronic kidney disease being the primary dri
